/ Print /

Mari Edlin
Mari Edlin is a frequent contributor to Managed Healthcare Executive. She is based in Sonoma, California.
Three ways technology is improving the pharmaceutical industry
Technology in pharmacy is leading to improved safety, accountability, and efficiency.
Specialty pharmaceuticals: Solving top challenges
Specialty pharmaceuticals: Solving top challenges
Managed Healthcare Executive recently invited a panel of experts representing different sectors of the healthcare industry to explore specialty pharmaceutical challenges and identify potential solutions.
CMS proposal to address antibiotic resistance: Key takeaways
To participate in Medicare and Medicaid, hospital and critical access hospitals (CAHs) would need to meet new criteria.
How four health plans are fighting the opioid epidemic
How four health plans are fighting the opioid epidemic
From new outreach programs to multidisciplinary teams, here are some new strategies health plans are employing to fight the opioid epidemic
Fall prevention strategies for hospitals
The CDC says that one out of three older adults falls each year, making falls the leading cause of injuries for adults 65 and older. Here’s how some hospitals and programs are addressing the problem.
What’s behind wide-scale hospital price variations?
What’s behind wide-scale hospital price variations?
Report offers some clues regarding healthcare spending disparities
Pharma coupons: pros and cons
Drug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed.
High-cost generic programs decrease drug spend in 5 plans
AMCP 2016 conference presenters from MedImpact outline their High-Cost Generic program that moves members to less-expensive, clinically relevant drug alternatives.
Predictions for the future of high-cost specialty drugs
IMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.
Five policy options to remedy value-based pricing
Value-based pricing raises concerns when it comes to drug affordability and experts discuss a call to action saying “prices no longer reflect costs.”